Tarextumab has been used in trials studying the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Tarextumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Tarextumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Tarextumab. |
| Estrone | Estrone may increase the thrombogenic activities of Tarextumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Tarextumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Tarextumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Tarextumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Tarextumab. |
| Estriol | Estriol may increase the thrombogenic activities of Tarextumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Tarextumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Tarextumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Tarextumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Tarextumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Tarextumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Tarextumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Tarextumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Tarextumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Tarextumab. |
| Equol | Equol may increase the thrombogenic activities of Tarextumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Tarextumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Tarextumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Tarextumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Tarextumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Tarextumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Tarextumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Tarextumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Tarextumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Tarextumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Tarextumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Tarextumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Tarextumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tarextumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Tarextumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Tarextumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Tarextumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tarextumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tarextumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Tarextumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tarextumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Tarextumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Tarextumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Tarextumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tarextumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tarextumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Tarextumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tarextumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tarextumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Tarextumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tarextumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Tarextumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Tarextumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Tarextumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tarextumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tarextumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Tarextumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Tarextumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Tarextumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Tarextumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Tarextumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Tarextumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Tarextumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Tarextumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Tarextumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Tarextumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Tarextumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Tarextumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Tarextumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Tarextumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Tarextumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Tarextumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Tarextumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Tarextumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Tarextumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Tarextumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Tarextumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Tarextumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Tarextumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Tarextumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Tarextumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Tarextumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Tarextumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Tarextumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Tarextumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Tarextumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Tarextumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Tarextumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Tarextumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tarextumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Tarextumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Tarextumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Tarextumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Tarextumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Tarextumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Tarextumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Tarextumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Tarextumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tarextumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Tarextumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Tarextumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Tarextumab. |